Tags : Avion

Avion Signs an Exclusive License Agreement with ImmuPharma to Develop

Shots: Immuphrama to receive $70M milestones including $5M as regulatory & $65M as commercialization milestones and up to 17% royalties on pre-specified annual US sales targets. ImmuPharma retains all rights to commercialize Lupuzor outside the US and receives an additional $5M on approval of Lupuzor for each additional indication (Ex- Lupus) Avion to get an […]Read More